SCHEMBL203700

SCHEMBL203700

O=C(O)CNCCc1ncc[nH]1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 2/20 0.59
TERT O14746 1/20 0.51
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TAAR1 Q96RJ0 2/20 0.39
NAMPT P43490 1/20 0.39
FDPS P14324 1/20 0.38
ADRB1 P08588 1/20 0.38
ADRB3 P13945 1/20 0.38
FPR2 P25090 1/20 0.38
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36
ALOX15 P16050 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
HRH4 Q9H3N8 1/20 0.36
PDCD1LG2 Q9BQ51 1/20 0.36
CD274 Q9NZQ7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034425 0.90 TBXAS1 (0.65) TBXAS1TERTGAASMN1; SMN2TAAR1
SCHEMBL24066797 0.85 TERT (0.50) TBXAS1TERTGAASMN1; SMN2TAAR1
SCHEMBL9077567 0.84 TBXAS1 (0.70) TBXAS1TERTGAASMN1; SMN2TAAR1
SCHEMBL2837061 0.83 TBXAS1 (0.54) TBXAS1TERTGAASMN1; SMN2TAAR1
SCHEMBL12807572 0.82 TERT (0.66) TBXAS1TERTTAAR1NAMPTFDPS
SCHEMBL434767 0.80 TBXAS1 (0.74) TBXAS1TERTGAASMN1; SMN2TAAR1
SCHEMBL30620153 0.80 TBXAS1 (0.74) TBXAS1TERTGAASMN1; SMN2TAAR1
SCHEMBL7426540 0.79 TERT (0.54) TBXAS1TERTGAASMN1; SMN2TAAR1
Water SCHEMBL27951668 0.79 TBXAS1 (0.58) TBXAS1TERTNAMPTKDM4EHRH4
Hydrochloric Acid SCHEMBL8937731 0.79 TBXAS1 (0.75) TBXAS1TERTGAASMN1; SMN2TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 898 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080233137-A1 Compounds that Block the C5a Receptor and Their Use in Therapy ALLIGATOR BIOSCIENCE AB (SE) 2008-09-25 US claimed
CN-1997664-A Compounds that block the C5A receptor and their use in therapy ALLIGATOR BIOSCIENCE AB PUBL (SE) 2007-07-11 CN claimed
EP-1737886-A2 COMPOUNDS THAT BLOCK THE C5A RECEPTOR AND THEIR USE IN THERAPY Alligator Bioscience AB (publ) (SE) 2007-01-03 EP claimed
WO-2005100385-A2 COMPOUNDS THAT BLOCK THE C5A RECEPTOR AND THEIR USE IN THERAPY ALLIGATOR BIOSCIENCE AB (PUBL) (SE) 2005-10-27 WO claimed
EP-1586583-A2 Compounds that block C5a complement receptor and their use in therapy Alligator Bioscience AB (publ) (SE) 2005-10-19 EP claimed
WO-2003006048-A1 COMBINATION OF CHIPS (CHEMOTAXIS INHIBITING PROTEIN FROM STAPHYLOCOCCUS AUREUS)-BASED COMPOUNDS JARI PHARMACEUTICALS B.V. (NL) 2003-01-23 WO claimed
US-20260140060-A1 COLORIMETRIC DETECTION OF A VIRAL INFECTION RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2026-05-21 US disclosed
US-20260124281-A1 FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE ENTERA BIO LTD. (IL) 2026-05-07 US disclosed
US-20260109870-A1 PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2026-04-23 US disclosed
US-12576191-B2 Method of inducing cardiomyocytes proliferation and treating heart diseases YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2026-03-17 US disclosed
US-20260069728-A1 MULTI-TARGETING COMPOUND AND USE THEREOF CHENGDU SHETAI MEDICAL TECHNOLOGY CO., LTD. (CN) 2026-03-12 US disclosed
EP-3980085-B1 COMPOSITIONS AND METHODS OF USING SAME FOR TISSUE REGENERATION UNIV RAMOT (IL) 2026-03-11 EP disclosed
EP-3606615-B1 METHOD OF STRAIGHTENING HAIR, METHOD FOR MAINTENANCE OF STRAIGHTENED HAIR AND KIT FOR STRAIGHTENING HAIR YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) 2026-01-07 EP disclosed
WO-1994003483-A1 ENDOTHELIN RECEPTOR-BINDING COMPOUNDS CHIRON CORPORATION (US) 1994-02-17 WO disclosed
US-5248689-A Hypotensive agents, congestive heart failure, renal failure or glaucoma SMITHKLINE BEECHAM CORPORATION (US) 1993-09-28 US disclosed
US-5234917-A Hypotensive agent, treatment of renal failure or glaucoma SMITHKLINE BEECHAM CORPORATION 1993-08-10 US disclosed
EP-0536262-A1 SUBSTITUTED HISTIDINES SMITHKLINE BEECHAM CORPORATION (US) 1993-04-14 EP disclosed
WO-1992000068-A1 SUBSTITUTED HISTIDINES SMITHKLINE BEECHAM CORPORATION (US) 1992-01-09 WO disclosed
EP-0437103-A2 Substituted 5-(alkyl)carboxamide imidazoles SMITHKLINE BEECHAM CORPORATION (US) 1991-07-17 EP disclosed
EP-0427463-A1 Substituted N-(imidazolyl)alkyl alanine derivatives SMITHKLINE BEECHAM CORPORATION (US) 1991-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124281-A1 FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE PTH1R, FGF23, PTMS TBXAS1 2780/4885TERT 2356/4885GAA 2077/4885
US-20260109870-A1 PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME NONO, NGLY1, PTMS TBXAS1 3111/4885TERT 1314/4885GAA 2713/4885
US-20260069728-A1 MULTI-TARGETING COMPOUND AND USE THEREOF CXCR4, CXCR2, GRPR TBXAS1 2299/4885TERT 3379/4885GAA 1126/4885
US-12576191-B2 Method of inducing cardiomyocytes proliferation and treating heart diseases MYLK2, TNNI3, MYL6 TBXAS1 3117/4885TERT 4060/4885GAA 4552/4885
US-20260140060-A1 COLORIMETRIC DETECTION OF A VIRAL INFECTION CTSL, CPA4, ACE2 TBXAS1 2879/4885TERT 1120/4885GAA 563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.